Cribriform-positive morphology was associated with a 3.6-fold higher risk for metastasis in patients with prostate cancer, and radiotherapy with neoadjuvant androgen deprivation therapy (ADT) was ...
Despite a lack of level 1 evidence, metastasis-directed therapy has been increasingly used for the treatment of oligometastatic prostate cancer based on findings from several randomized phase II ...
*Classification performance AUC and balanced accuracy (mean and std, %) using case-level bags on final tiles with a fixed feature setting and dino cls keep=4. Best result per column in bold. This is ...
Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...
Morning Overview on MSN
A prostate cancer drug halved the odds of the disease spreading
Men diagnosed with high-risk localized prostate cancer now have trial-level evidence that adding the drug apalutamide to ...
First patients dosed in OPTIMAL-e1 Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St ...
Clinicians report that early AKT inhibition side effects are manageable, allowing four out of five patients to maintain ...
Akeega prostate cancer UK approval: the MHRA has licensed Johnson and Johnson's niraparib-abiraterone combination for men ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results